timonensis might explain a portion of TMAO production from carnitine consumption in human but still required to be validated with a larger cohort
Kasi, PM, Rivero, S, Aushev, VN, Langer, N, Wang, CG, Cannon, TL, Berim, L, Feinstein, TM, Grothey, A, McCollom, JW, Kalmadi, S, Zakari, A, Dayyani, F, Gravenor, D, Meyer, JM, Sharif, S, Jurdi, A, Liu, MC, Aleshin, A, Kopetz, S
Another milestone in the evolution of GLP-1-based diabetes therapies
While commercial sources of copper(I), such as cuprous bromide or iodide, can be utilized, the reaction is notably more effective when conducted with a combination of copper(II) and a reducing agent (e.g., sodium ascorbate) to generate Cu(I) in situ
Injury or tissue repair D